|
Characteristics of the 33 selected randomised controlled trials and the patients studied in them |
||||||||||||
| N |
Randomized controlled trial |
Year |
Country |
Treatment |
Level of care |
% of women |
Mean age |
Length of treatment (years) |
Simple size |
Oxford scoring (quality) |
Duration of disease at baseline (years) |
Instruments used (outcome assessed) |
|
|
||||||||||||
| 1 |
Carette |
94 |
Canada |
Amitryptiline Cyclobenzaprine |
Primary care |
93.8 |
44.4 |
24 |
208 |
3 |
7.7 |
Mc Gill-BPI (p) SIP (gf) |
| 2 |
Russell |
94 |
USA |
Malic acid |
Specialised care |
90 |
49.5 |
8 |
24 |
3 |
VAS (p) TPI (tp) |
|
| 3 |
Wolfe |
94 |
USA |
Fluoxetine |
Primary care |
100 |
50.4 |
3 |
42 |
5 |
13 |
TPI (tp) BDI (ad) |
| 4 |
Carette |
95 |
Canada |
Amitryptiline |
Primary care |
95.5 |
43.8 |
8 |
22 |
2 |
6.9 |
VAS (p) VAS (i) VAS (gf) |
| 5 |
Chesky |
95 |
USA |
Music vibration |
Specialised care |
92.6 |
48.8 |
30 minutes |
26 |
3 |
11 |
VAS (p) TPI (tp) |
| 6 |
Goldenberg |
96 |
USA |
Fluoxetine Amitryptiline |
Primary care |
90.3 |
43 |
6 |
31 |
5 |
5.7 |
VAS (p) FIQ (GF) BDI (ad) VAS (i) VAS (gf) VAS (f) TPI (tp) |
| 7 |
Ginsberg |
96 |
Belgium |
Amitryptiline |
Primary care |
82.5 |
46 |
8 |
46 |
2 |
32 |
VAS (p) VAS (i) TPI (tp) VAS (f) VAS (gf) NTP (tp) |
| 8 |
Moldofsky |
96 |
Canada |
Zolpidem |
Primary care |
95 |
42 |
2.5 |
19 |
4 |
NTP (tp) PGI (i) |
|
| 9 |
Vlayen |
96 |
Holland |
Cognitive behavioural therapy Education training |
Specialised care |
87 |
44 |
6 |
131 |
5 |
10 |
BDI (ad) |
| 10 |
Wigers |
96 |
Norway |
Aerobic exercise Stress-reduction treatment |
Specialised care |
92 |
44 |
14 |
48 |
3 |
10 |
VAS (p) VAS (i) VAS (f) |
| 11 |
Pearl |
96 |
Canada |
Bright light treatment |
Specialised care |
100 |
38 |
10 |
14 |
2 |
5 |
VAS (p) VAS (f) VAS (i) |
| 12 |
Kelli |
97 |
Canada |
Chiropractic treatment |
Specialised care |
- |
49 |
4 |
19 |
4 |
8 |
VAS (p) NTP (tp) |
| 13 |
Hannonen |
98 |
Finland |
Moclobemide Amitryptiline |
Primary care |
100 |
49 |
12 |
130 |
5 |
11.2 |
NTP (tp) VAS (p) VAS (f) VAS (i) |
| 14 |
Yavuzer |
98 |
Turkey |
Moclobemide |
Primary care |
58 |
33 |
6 |
60 |
1 |
TPI (tp) |
|
| 15 |
Ginsberg |
98 |
Belgium |
Pirlindole |
Specialised care |
85 |
40 |
4 |
61 |
4 |
2.9 |
VAS (p) TPI (tp) VAS (gf) |
| 16 |
Russell |
00 |
USA |
Tramadol |
Primary care |
94 |
49 |
6 |
69 |
4 |
4.7 |
VAS (p) FIQ (gf) NTP (tp) |
| 17 |
Heymann |
01 |
Brazil |
Amitryptiline Nortryptiline |
Primary care |
100 |
50 |
8 |
118 |
4 |
FIQ (gf) NTP (tp) |
|
| 18 |
Färber |
01 |
Germany |
Tropisetron |
Specialised care |
92 |
48 |
1.5 |
403 |
3 |
11 |
Vas (p) NTP (tp) |
| 19 |
Gowans |
01 |
Canada |
Exercise |
Specialised care |
88 |
47 |
23 |
50 |
3 |
9 |
FIQ (gf) BDI (ad) STAI (ad) NTP (tp) |
| 20 |
Mannerkorpi |
01 |
Sweden |
Education training |
Specialised care |
100 |
46 |
24 |
58 |
4 |
8.7 |
FIQ (gf) QOLS (ql) |
| 21 |
Gür |
02 |
Turkey |
Laser Amitryptiline |
Primary care (Amytriptiline) – Specialised care (laser) |
80 |
30 |
8 |
75 |
3 |
4.6 |
HADS (ad) FIQ (gf) |
| 22 |
Joaquim |
02 |
Sweden |
Education training Behavioural therapy |
Specialised care |
100 |
45 |
12 |
53 |
6 |
3.6 pain |
FIQ (gf) Mc Gill (p) |
| 23 |
King |
02 |
Canada |
Exercise Education training |
Specialised care |
100 |
46 |
12 |
152 |
4 |
FIQ (gf) NTP (tp) |
|
| 24 |
Lemstra |
05 |
Canada |
Rehabilitation |
Specialised care |
84.5 |
49.5 |
6 |
79 |
3 |
10 |
VAS (p) BDI (ad) |
| 25 |
Schachter |
03 |
Canada |
Aerobic exercise (long-term and short-term) |
Specialised care |
100 |
42 |
16 |
143 |
4 |
3.5 |
VAS (p) FIQ (gf) |
| 26 |
Arnold |
04 |
USA |
Duloxetine |
Primary care |
88 |
49 |
12 |
207 |
6 |
8.9 |
BDI (ad) BPI (ad) NTP (tp) CGI (gf) FIQ (gf) |
| 27 |
Yildiz |
04 |
Turkey |
Hyperbaric oxigen therapy |
Specialised care |
70 |
40 |
2.5 |
50 |
2 |
4.5 |
VAS (p) NTP (tp) |
| 28 |
Crofford |
05 |
USA |
Pregabaline |
Primary care |
92 |
48.5 |
8 |
529 |
5 |
9 |
VAS (p) MAF (f) |
| 29 |
Arnold |
05 |
USA |
Duloxetine |
Primary care |
100 |
50 |
12 |
354 |
5 |
BPI (ad) |
|
| 30 |
Gendreau |
05 |
USA |
Milnacipran |
Primary care |
98 |
47 |
12 |
125 |
6 |
4.1 |
FIQ (gf) |
| 31 |
Finckh |
05 |
Switzerland |
Dehydroepiandrosterone (DHA) |
Specialised care |
100 |
59 |
12 |
52 |
6 |
13 |
HADS (ad) VAS (f) |
| 32 |
Holman |
05 |
USA |
Pramipexole |
Specialised care |
94.4 |
48.5 |
14 |
60 |
6 |
8.4 |
BDI (ad) HAMD (ad) TPI (tp) FIQ (gf) |
| 33 |
Edinger |
05 |
USA |
Cognitive behavioural therapy Sleep hygiene |
Specialised care |
100 |
49 |
6 |
47 |
3 |
Mc Gill (p) BPI (ad) SF-36 (ql) |
|
|
Outcome types: P, Pain; QL, Quality of life; AD, Anxiety-depression; I, Insomnia; TP, Tender points; F, Fatigue; GF, Global Function. Questionnaires: Mc Gill PQ, Mc Gill Pain Questionnaire; BPI, Brief Pain Inventory; VAS, Visual Analogue Scale; QOLS, Quality of Life Scale; BDI, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale; HDS, Hamilton Depression Scale; STAI, State-trait Anxiety Inventory; PGI, Patient Global Impression; TPI, Tender Points Index; MAF, Multi-dimensional Assessment of Fatigue; FIQ, Fibromyalgia Impact Questionnaire; CGIS, Clinical Global Impression of Severity; SIP, Sickness Impact Profile. | ||||||||||||
Garcia-Campayo et al. Arthritis Research & Therapy 2008 10:R81 doi:10.1186/ar2455 |
||||||||||||